CDC42 Antibody (3193C) [Unconjugated]

Western Blot shows lysates of Jurkat human acute T cell leukemia cell line. PVDF membrane was probed with 2 µg/ml of Rabbit Anti-Human CDC42 Monoclonal Antibody (Catalog # MAB11765) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for CDC42 at approximately 21 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.

• Reactivity: Hu
• Applications: WB
• Clone: 3193C
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated

CDC42 Antibody (3193C) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Synthetic Peptide
  Accession # P60953
• Specificity: Detects a synthetic peptide specific for human CDC32 around amino acid 140 in Direct ELISA.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • Western Blot 2 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Reconstitution Instructions: Reconstitute lyophilized material at 0.2 mg/ml in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CDC42 Antibody (3193C) [Unconjugated]

• CDC42
• CDC42Hs
• cell division control protein 42 homolog
• cell division cycle 42 (GTP binding protein, 25kDa)
• cell division cycle 42 (GTP-binding protein, 25kD)
• dJ224A6.1.1 (cell division cycle 42 (GTP-binding protein, 25kD))
• dJ224A6.1.2 (cell division cycle 42 (GTP-binding protein, 25kD))
• G25K GTP-binding protein
• G25K
• growth-regulating protein
• GTP-binding protein, 25kD
• small GTP binding protein CDC42

Background

Cell division control protein 42 (CDC42) is a small Rho GTPase with a molecular weight of approximately 21 kDa. CDC42 is a highly conserved protein that plays an integral role in regulating multiple cellular processes, including cytoskeletal organization, cell polarity, vesicle trafficking, and signal transduction. A key regulator of the actin cytoskeleton, CDC42 is critical for the formation of filopodia, which are dynamic, actin-rich cell protrusions involved in sensing the extracellular environment. CDC42 is ubiquitously expressed across eukaryotic cells and contributes to essential biological functions such as cell migration, adhesion, and mitotic spindle orientation. Dysregulation of CDC42 activity is implicated in a variety of pathological conditions, including cancer metastasis, where it drives tumor cell migration and invasion, as well as immune disorders resulting from aberrant cell polarization and trafficking. Mutations in genes regulating CDC42 and its activity are associated with developmental disorders, such as Takenouchi-Kosaki syndrome. Given its central role in cellular signaling and cytoskeletal dynamics, CDC42 is a key player in numerous physiological and pathological contexts, making it a valuable biomarker and therapeutic target.

1. Ridley AJ. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol. 2006 Oct;16(10):522-9. doi: 10.1016/j.tcb.2006.08.006. Epub 2006 Sep 1. PMID: 16949823.
2. Johnson DI. Cdc42: An essential Rho-type GTPase controlling eukaryotic cell polarity. Microbiol Mol Biol Rev. 1999 Mar;63(1):54-105. doi: 10.1128/MMBR.63.1.54-105.1999. PMID: 10066831; PMCID: PMC98957.
3. Jahid S, Ortega JA, Vuong LM, Acquistapace IM, Hachey SJ, Flesher JL, La Serra MA, Brindani N, La Sala G, Manigrasso J, Arencibia JM, Bertozzi SM, Summa M, Bertorelli R, Armirotti A, Jin R, Liu Z, Chen CF, Edwards R, Hughes CCW, De Vivo M, Ganesan AK. Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer. Cell Rep. 2022 Apr 5;39(1):110641. doi: 10.1016/j.celrep.2022.110641. Erratum in: Cell Rep. 2022 Apr 26;39(4):110760. doi: 10.1016/j.celrep.2022.110760. PMID: 35385746; PMCID: PMC9127750.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P60953(Human)